fda glp-1 compounding crackdown news october 2025 is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA warns against compounded GLP-1

The brand's published materials don't specify a standard timeline, referencing consistent use as the basis for supporting healthier metabolic processes over time

Close monitoring of blood sugar is essential, particularly if you frequently feel tired, to allow for timely adjustments to medication or diet

They make the category investable By standardizing CAC, retention, staffing, and fulfillment, they make it easier for growth funds to invest downstream

It often takes time to come to terms with a breast cancer diagnosis

Semaglutide may worsen diabetic retinopathy in some patients with pre-existing disease, particularly during rapid improvement in glucose control